X4 Pharmaceuticals Cuts Workforce by 30% to Focus on Mavorixafor for Chronic Neutropenia, Scales Back Research to Prioritize Rare Disease Treatments

X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, announced today a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat those with chronic neutropenia, while also optimizing its U.S. promotion of XOLREMDI® (mavorixafor), approved for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare immunodeficiency.

Strategic restructuring activities include:

• Reducing overall headcount by 43 people (approximately 30% of X4 employees), which includes discontinuing research efforts and closing the company's facility in Vienna, Austria, as well as pausing pre-clinical drug candidate programs;
• Scaling the U.S. commercial field team and supporting roles across the company;
• Streamlining other spending to support the ongoing clinical development of mavorixafor for the larger population of those with chronic neutropenia.